Activity Description:

As clinical practice guidelines are created and/or updated for the Colorado Blood Cancer Institute, individual meetings will be held for educational purposes. Specific treatment guidelines will be reviewed during each meeting, with supporting data provided. Open discussion will be encouraged.

At this meeting, participants will review the following SOPs: IET-SOP-1300.05 Toxicity Management of Immune Effector Cell Therapy Recipients and IET-SOP-1400.03 IECT Supportive Care. In addition, we will cover the topic of PJP prophylaxis and toxoplasmosis prophylaxis and monitoring which will be added to the revised BMT-SOP Management of Late Effects in the Post-HSCT Setting.

Target Audience: 

CBCI providers (physicians and APPs) and nurses who care for CBCI patients.

Learning Objectives:

1. Identify evolving management of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
2. Evaluate the refined algorithm/workflows for management of outpatient CAR T-cell therapy recipients.
3. Ability to identify and manage Immune-Effector Cell-Associated Hemophagocytic Lymphohistiocytosis (HLH)-like Syndrome (IEC-HS).
4. Utilize the CAR-Hematotox (HT) score and practical applications.
5. Apply updates for prevention of infections in CAR T-cell therapy recipients.
6. Comprehend PJP prophylaxis and toxoplasmosis prophylaxis, and monitoring with Allo HSCT.

Moderator:

Alison Colings, NP-C

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Accreditation:

The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Credit Designation:

The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:  

This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: 

The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.